If you'd invested in: GW Pharmaceuticals and Trinity Mirror

GW Pharmaceuticals (LSE:GWP) is a UK-based biopharmaceutical company making medicine from cannabis. Its headline product is Sativex, used to treat pain and other symptoms in patients with multiple sclerosis. It is also developing a drug to treat children with epilepsy, which is currently undergoing phase III trials. The latest annual report showed a pre-tax loss of £57m on revenue of £28.5m. Nevertheless, investors are enthusiastic the share price is up by almost 90% in the last year.

Be glad you didn't

Trinity Mirror (LSE: TNI) is the country's biggest newspaper, magazine and digital publisher, with more than 260 titles. Like many other publishers, Trinity Mirror is feeling the pinch as print sales decline, advertising revenue dries up and online operations fail to pay their way. The company is cutting costs by consolidating editorial teams and closing unprofitable titles. But profits and revenue continue to fall, and they have been followed by the share price, which is down by more than 50% in the last year.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up